Kestra Private Wealth Services LLC Sells 4,827 Shares of Cencora, Inc. (NYSE:COR)

Kestra Private Wealth Services LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 33.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,692 shares of the company’s stock after selling 4,827 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Cencora were worth $2,178,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. WCM Investment Management LLC grew its holdings in Cencora by 99.1% in the 4th quarter. WCM Investment Management LLC now owns 2,116 shares of the company’s stock worth $476,000 after acquiring an additional 1,053 shares during the last quarter. Apollon Wealth Management LLC boosted its holdings in shares of Cencora by 14.1% during the fourth quarter. Apollon Wealth Management LLC now owns 5,353 shares of the company’s stock worth $1,203,000 after purchasing an additional 660 shares during the period. Shepherd Financial Partners LLC grew its stake in shares of Cencora by 0.9% in the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company’s stock worth $1,223,000 after purchasing an additional 46 shares during the last quarter. Generate Investment Management Ltd increased its holdings in Cencora by 92.4% during the 4th quarter. Generate Investment Management Ltd now owns 46,508 shares of the company’s stock valued at $10,449,000 after purchasing an additional 22,330 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its position in Cencora by 4.4% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,575 shares of the company’s stock valued at $6,420,000 after purchasing an additional 1,200 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on COR shares. Wells Fargo & Company lifted their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Robert W. Baird lifted their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, UBS Group increased their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Cencora Price Performance

Shares of COR opened at $246.86 on Wednesday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The firm’s 50-day simple moving average is $238.86 and its two-hundred day simple moving average is $237.03. The stock has a market cap of $47.71 billion, a PE ratio of 35.11, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Analysts anticipate that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Friday, February 14th. Cencora’s dividend payout ratio is presently 31.29%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,187 shares of company stock worth $17,790,912 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.